Cancer Treatment Reviews
Volume 24, Issue 4 , Pages 265-281 , August 1998

Cumulative toxicities from cisplatin therapy and current cytoprotective measures

  • E. Cvitkovic

      Affiliations

    • Corresponding Author InformationCorrespondence: E. Cvitkovic, SMSIT, Hopital Paul Brouss 12-14 Avenue Paul Vaillant Couturier, 94804 Villejuif Cedex, France.

References 

  1. Loehrer PJ, Einhorn LH. Cisplatin. Ann Intern Med. 1984;100:704–713
  2. Wallace HJ, Higby DJ. Phase I evaluation of cis-platinum (II) diamminedichloride (PDD) and a combination of PDD plus Adriamycin. In:  Connors TA,  Roberts JJ editor. Platinum Coordination Complexes in Cancer Chemotherapy. Recent Results in Cancer Research. vol 48:New York: Springer; 1994;p. 167–177
  3. Wiltshaw E, Carr B. cis-Platinum (II) diamminedichloride: clinical experience of the Royal Marsden Hospital and Institute of Cancer Research, London. In:  Connors TA,  Roberts JJ editor. Platinum Coordination Complexes in Cancer Chemotherapy. Recent Results in Cancer Research. vol48:New York: Springer; 1974;p. 178–182
  4. Hayes DM, Cvitkovic E, Golbey RB, Schemer E, Helson L, Krakoff IH. High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis. Cancer. 1977;39:1372–1381
  5. Ozols RF. Cisplatin dose intensity. Semin Oncol. 1989;16(Suppl. 6):22–30
  6. Kaye SB, Lewis CR, Paul J, et al.  Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet. 1992;340:329–333
  7. Alberts DS, Garcian DJ. Total platinum dose versus platinum dose intensificaion in ovarian cancer treatment. Semin Oncol. 1994;21(Suppl. 2):11–15
  8. Daugaard G, Abildgaard U. Cisplatin nephrotoxicity: a review. Cancer Chemother Pharmacol. 1989;25:1–9
  9. Anand AJ, Bashey B. Newer insights into cisplatin nephrotoxicity. Ann Pharmacother. 1993;27:1519–1525
  10. Cersosimo RJ. Cisplatin neurotoxicity. Cancer Treat Rev. 1989;16:195–211
  11. Alberts DS, Noel JK. Cisplatin-associated neurotoxicity: can it be prevented?. Anticancer Drugs. 1995;6:369–383
  12. Roila F, Tonato M, Basurto C, et al.  Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine: a study of the Italian Oncology Group for Clinical Research. J Clin Oncol. 1989;7:1693–1700
  13. Roila F, Palladino MA, Ciccarese G, Basurto C. Recent improvements in antiemetic therapy. Tumori. 1997;83(Suppl. 2):S3–S14
  14. Tavorath R, Hesketh PJ. Drug treatment of chemotherapyinduced delayed emesis. Drugs. 1996;52:639–648
  15. O'Callaghan A, Mead GM. Testicular carcinoma. Postgrad Med j. 1997;73:481–486
  16. Kennedy BJ, Torkelson J, Fraley EE. Optimal number of chemotherapy courses in advanced nonseminomatous testicular carcinoma. Am J Clin Oncol. 1995;18:463–468
  17. West RJ, Zweig SF. Meta-analysis of chemotherapy regimens for ovarian carcinoma: a reassessment of cisplatin, cyclophosphamide and doxorubicin versus cisplatin and cyclophosphamide. Eur J Gynaecol Oncol. 1997;18:343–348
  18. Walther PJ. Combined treatment approaches in regionally advanced bladder cancer. Urol Clin North Am. 1992;19:761–774
  19. Malmstrom PU, Rintala E, Wahlqvist R, Hellstrom P, Hellsten S, Hannisdal E. Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I: The Nordic Cooperative Bladder Cancer Study Group. I Urol. 1996;155:1903–1906
  20. Sandler AB. Current management of small cell lung cancer. Semin Oncol. 1997;24:463–476
  21. The American Society of Clinical Oncology . Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer: adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol. 1997;15:2996–3018
  22. Bonomi P. Eastern Cooperative Oncology Group experience with chemotherapy in advanced non-small cell lung cancer. Chest. 1998;113(Suppl. 1):13S–16S
  23. Vokes EE. Combined-modality therapy of head and neck cancer. Oncology (Huntingt). 1997;11(Suppl. 9):27–30
  24. Harari PM. Why has induction chemotherapy for advanced head and neck cancer become a United States community standard of practice?. J Clin Oncol. 1997;15:2050–2055
  25. Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group J Natl Cancer Inst. 1996;88:890–899
  26. Link KH, Gansauge F, Gorich J, Leder GH, Rilinger N, Beger HG. Palliative and adjuvant regional chemotherapy in pancreatic cancer. Eur J Surg Oncol. 1997;23:409–414
  27. Okusaka T, Okada S, Ishii H, et al.  Clinical response to systemic combined chemotherapy with 5-fluorouracil and cisplatin (FP therapy) in patients with advanced pancreatic cancer. Jpn J Clin Oncol. 1996;26:215–220
  28. Wasserheit C, Frazein A, Oratz R, et al.  Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity. J Clin Oncol. 1996;14:1993–1999
  29. Ezzat A, Raja MA, Berry J, et al.  A phase II trial of circadiantimed paclitaxel and cisplatin therapy in metastatic breast cancer. Ann Oncol. 1997;8:663–667
  30. Souhami RL, Craft AW, Van der Eijken JW, et al.  Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet. 1997;350:911–917
  31. Atkins MB. The treatment of metastatic melanoma with chemotherapy and biologics. Curr Opin Oncol. 1997;9:205–213
  32. McGuire WP, Hoskins WJ, Brady MF, et al.  Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 1995;13:1589–1599
  33. Kaye SB, Cassidy PJ, Lewis CR, et al.  Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. J Clin Oncol. 1996;14:2113–2119
  34. Conte PF, Bruzzone M, Carnino F, et al.  High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest. J Clin Oncol. 1996;14:351–356
  35. Clamon GH, Baatz L, Hoffman HT, et al.  Neurotoxicity in a phase I trial of continuous infusion cisplatin with hyperfractionated radiotherapy for locally advanced head and neck cancer. Head Neck. 1996;18:236–241
  36. Mollman JE, Glover DJ, Hogan WM, et al.  Cisplatin neuropathy. In: Risk factors, prognosis, and protection by WR-2721. Cancer. 61:1988;p. 2192–2195
  37. Hilkens PH, van der Burg ME, Moll JW, et al.  Neurotoxicity is not enhanced by increased dose intensities of cisplatin administration. Eur J Cancer. 1995;31A:678–681
  38. Fjeldborg P, Sorensen J, Helkjaer PE. The long-term effect of cisplatin on renal function. Cancer. 1986;58:2214–2217
  39. Aass N, Fossa SD, Aas M, Lindegaard MW. Renal function related to different treatment modalities for malignant germ cell tumours. Br J Cancer. 1990;62:842–846
  40. Meijer S, Mulder NH, Sleijfer DT, et al.  Influence of combination chemotherapy with cis-diamminedichloroplatinum on renal function: long-term effects. Oncology. 1983;40:170–173
  41. Brillet G, Deray G, Jacquiaud C, et al.  Long-term renal effect of cisplatin in man. Am J Nephrol. 1994;14:81–84
  42. Osanto S, Bukman A, Van Hoek F, Sterk PJ, De Laat JA, Hermans J. Long-term effects of chemotherapy in patients with testicular cancer. J Clin Oncol. 1992;10:574–579
  43. Brillet G, Deray G, Lucsko M, et al.  Definitive end-stage chronic kidney failure after cisplatin treatment. Nephrologie. 1993;14:227–229
  44. Ariceta G, Rodriguez-Soriano J, Vallo A, Navajas A. Acute and chronic effects of cisplatin therapy on renal magnesium homeostasis. Med Pediatr Oncol. 1997;28:35–40
  45. Canpolat C, Pearson P, Jaffe N. Cisplatin-associated hemolytic uremic syndrome. Cancer. 1994;74:3059–3062
  46. Daugaard G, Rossing N, Rorth M. Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose. Cancer Chemother Pharmacol. 1988;21:163–167
  47. Groth S, Nielsen H, Sorensen JB, Christensen AB, Pedersen AG, Rorth M. Acute and long-term nephrotoxicity of cisplatinum in man. Cancer Chemother Pharmacol. 1986;17:191–196
  48. Daugaard G, Abildgaard U, Holstein-Rathlou N-H, Bruunshuus I, Bucher D, Leyssacpp PP. Renal tubular function in patients treated with high-dose cisplatin. Clin Pharmacol Ther. 1988;44:164–172
  49. Dentino M, Luft FC, Yum MN, Williams SD, Einhorn LH. Long term effect of cis-diamminedichloride platinum (CDDP) on renal function and structure in man. Cancer. 1978;41:1274–1281
  50. Kim YK, Byun HS, Kim YH, Woo JS, Lee SH. Effect of cisplatin on renal function in rabbits: mechanism of reduced glucose reabsorption. Toxicol Appl Pharmacol. 1995;130:19–26
  51. Leibbrandt ME, Wolfgang GH, Metz AL, Ozobia AA, Haskins JR. Critical subcellular targets of cisplatin and related platinum analogs in rat renal proximal tubule cells. Kidney Int. 1995;48:761–770
  52. Hannemann J, Baumann K. Cisplatin-induced lipid peroxidation and decrease of gluconeogenesis in rat kidney cortex: different effects of antioxidants and radical scavengers. Toxicology. 1988;51:119–132
  53. Kruidering M, Van de Water B, de Heer E, Mulder GJ, Nagelkerke JF. Cisplatin-induced nephrotoxicity in porcine proximal tubular cells: mitochondrial dysfunction by inhibition of complexes I to IV of the respiratory chain. J Pharmacol Exp Ther. 1997;280:638–649
  54. Sugiyama S, Hayakawa M, Kato T, Hanaki Y, Shimizu K, Ozawa T. Adverse effects of antitumor drug, cisplatin, on rat kidney mitochondria: disturbances in glutathione peroxidase activity. Biochem Biophys Res Commun. 1989;159:1121–1127
  55. Dewitt LM, Jones TW, Moore L. Stimulation of the renal endoplamic reticulum calcium pump: a possible biomarker for platinate toxicity. Toxicol Appl Pharmacol. 1988;92:157–169
  56. Goren MP, Wright RK, Horowitz ME. Cumulative renal tubular damage associated with cisplatin nephrotoxicity. Cancer Chemother Pharmacol. 1986;18:69–73
  57. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41
  58. Frennby B, Sterner G, Almen T, Chai CM, Jonsson BA, Mansson S. Clearance of iohexol, 51Cr-EDTA and endogenous creatinine for determination of glomerular filtration rate in pigs with reduced renal function: a comparison between different clearance techniques. Scand J Clin Lab Invest. 1997;57:241–252
  59. Toto RD. Conventional measurement of renal function utilizing serum creatinine, creatinine clearance, inulin and paraaminohippuric acid clearance. Curr Opin Nephrol Hypertens. 1995;4:505–509
  60. Donadio C, Lucchesi A, Tramonti G, Bianchi C. Creatinine clearance predicted from body cell mass is a good indicator of renal function. Kidney Int Suppl. 1997;63:S166–S168
  61. Rao PS, Fiorica JV, Shah RP, et al.  The clinical significance of calculated versus measured creatinine clearance in patients with gynecologic malignancy. South Med J. 1996;89:967–970
  62. Ikeda H, Nagashima K, Okumura H, Takahashi A, Matsuyama S, Nagamachi Y. Urinary excretion of beta 2-microglobulin and N-acetyl-beta-d-glucosaminidase in advanced neuroblastoma patients receiving cis-diamminedichloroplatinum(II). Eur J Surg Oncol. 1988;14:17–20
  63. Hayashi M, Numaguchi M, Watabe H, et al.  Cisplatin-induced nephrotoxicity and the protective effect of fosfomycin on it as demonstrated by using a crossover study of urinary metabolite levels. Acta Obstet Gynecol Scand. 1997;76:590–595
  64. Schilsky RL, Anderson T. Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. Ann Intern Med. 1979;90:929–931
  65. Buckley JE, Clark VL, Meyer TJ, et al.  Hypomagnesemia after cisplatin combination chemotherapy. Arch Intern Med. 1984;144:2347–2348
  66. Bell DR, Woods RL, Levi JA. cis-Diamminedichloroplatinuminduced hypomagnesemia and renal magnesium wasting. Eur J Cancer. 1985;21:287–290
  67. Gomez Campdera FJ, Gonzalez P, Carrillo A, et al.  Cisplatin nephrotoxicity: symptomatic hypomagnesemia and renal failure. Int J Pediatr Nephrol. 1986;7:151–152
  68. Hutchison FN, Perez EA, Gandara DR, et al.  Renal salt wasting in patients treated with cisplatin. Ann Intern Med. 1988;108:21–25
  69. Bianchetti MG, Kanaka C, Ridolfi-Luthy A, Hirt A, Wagner HP, Oetliker OH. Persisting renotubular sequelae after cisplatin in children and adolescents. Am I Nephrol. 1991;11:127–130
  70. Lee YK, Shin DM. Renal salt wasting in patients treated with high-dose cisplatin, etoposide, and mitomycin in patients with advanced non-small cell lung cancer. Korean I Intern Med. 1992;7:118–121
  71. Peyrade F, Taillan B, Lebrun C, Bendini JC, Passerron C, Dujardin P. Hyponatremia during treatment with cisplatin. Presse Med. 1997;26:1523–1525
  72. Li L, Huang W, Zhu B. Hypomagnesemia in patients of gynecologic neoplasms following chemotherapy with cisplatin. Chung Hua Fu Chan Ko Tsa Chih. 1995;30:363–365
  73. Schilsky RL, Barlock A, Ozols RE. Persistent hypomagnesemia following cisplatin chemotherapy for testicular cancer. Cancer Treat Rep. 1982;66:1767–1769
  74. Vogelzang NJ, Torkelson JL, Kennedy BJ. Hypomagnesemia, renal dysfunction, and Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin. Cancer. 1985;56:2765–2770
  75. Markmann M, Rothman R, Reichman B, et al.  Persistent hypomagnesemia following cisplatin chemotherapy in patients with ovarian cancer. J Cancer Res Clin Oncol. 1991;117:89–90
  76. Kavanagh J, Tresukosol D, Edwards C, et al.  Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer. J Clin Oncol. 1995;13:1584–1588
  77. Curt GA, Grygiel JJ, Corden BJ, et al.  A phase I and pharmacokinetic study of diamminecyclobutane-dicarboxylatoplatinum (NSC 241240). Cancer Res. 1983;43:4470–4473
  78. Harland SJ, Newsell DR, Siddik ZH, et al.  Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function. Cancer Res. 1984;44:1693–1697
  79. Egorin MJ, Van Echo DA, Tipping SJ, et al.  Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function. Cancer Res. 1984;44:5432–5438
  80. Calvert AH, Newell DR, Gumbrell LA, et al.  Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989;7:1748–1756
  81. Trump DL, Grem JL, Tutsch KD, et al.  Platinum analogue combination chemotherapy: cisplatin and carboplatin-A phase I trial with pharmacokinetic assessment of the effect of cisplatin administration on carboplatin excretion. J Clin Oncol. 1987;5:1281–1289
  82. Lund B, Hansen M, Hansen OP, et al.  High-dose platinum consisting of combined carboplatin and cisplatin in previously untreated ovarian cancer patients with residual disease. J Clin Oncol. 1989;7:1469–1473
  83. Jodrell DI, Egorin MJ, Canetta RM, et al.  Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol. 1992;10:520–528
  84. Vallejos C, Solidoro A, Gomez H, et al.  Ifosfamide plus cisplatin as primary chemotherapy of advanced ovarian cancer. Gynecol Oncol. 1997;67:168–171
  85. Leone B, Vallejo C, Perez J, et al.  Ifosfamide and cisplatin as neoadjuvant chemotherapy for advanced cervical carcinoma. Am J Clin Oncol. 1996;19:132–135
  86. Cervellino JC, Araujo CE, Sanchez O, Miles H, Nishihama A. Cisplatin and ifosfamide in patients with advanced squamous cell carcinoma of the uterine cervix: a phase II trial. Acta Oncol. 1995;34:257–259
  87. Miller VA, Rigas JR, Pisters KM, et al.  Ifosfamide plus highdose cisplatin in patients with non-small cell lung cancer previously treated with chemotherapy. Am J Clin Oncol. 1995;18:303–306
  88. Budd GT, Metch B, Weiss SA, et al.  Phase II trial of ifosfamide and cisplatin in the treatment of metastatic sarcomas: a Southwest Oncology Group study. Cancer Chemother Pharmacol. 1993;31(Suppl. 2):S213–S216
  89. Pratt CB, Meyer WH, Jenkins JJ, et al.  Ifosfamide, Fanconi s syndrome, and rickets. J Clin Oncol. 1991;9:1495–1499
  90. Goren MP, Wright RK, Pratt CB, et al.  Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cis-diamminedichloroplatinum(II) therapy. Cancer Res. 1987;47:1457–1460
  91. Perez EA, Sowray PC, Gardner SL, et al.  Phase I study of high-dose cisplatin, ifosfamide, and etoposide. Cancer Chemother Pharmacol. 1994;34:331–334
  92. Graziano SL, Herndon JE, Richards F, et al.  A phase I trial of ifosfamide, mesna, and cisplatin in advanced non-small cell lung cancer. Cancer. 1993;72:62–68
  93. Wheeler BM, Loehrer PJ, Williams SD, et al.  Ifosfamide in refractory male germ cell tumors. J Clin Oncol. 1986;4:28–34
  94. Niederle N, Scheulen ME, Cremer M, et al.  Ifosfamide in combination chemotherapy for sarcomas and testicular carcinomas. Cancer Treat Rev. 1983;10:129–135 (Suppl.)
  95. Saxman SB, Propert KJ, Einhorn LH, et al.  Long-term followup of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1997;15:2564–2569
  96. Loehrer PJ, Einhorn LH, Elson PJ, et al.  A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1992;10:1066–1073
  97. Morrell LE, Lee YJ, Hurley J, et al.  A phase II trial of neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin in the treatment of patients with locally advanced breast carcinoma. Cancer. 1998;82:503–511
  98. Langer CJ, Catalano R, Weiner LM, et al.  Phase II evaluation of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) in advanced, measurable breast carcinoma. Cancer Invest. 1995;13:150–159
  99. Bisagni G, Cocconi G, Ceci G, et al.  M-VAC combination in locally advanced, locally recurrent or metastatic breast carcinoma: a phase II study. Ann Oncol. 1994;5:93–94
  100. Bleyer WA. The clinical pharmacology of methotrexate. Cancer. 1978;41:36–51
  101. Balbay MD, Ozen H, Ulucay S, et al.  Methotrexate, vinblastine, adriamycin and cisplatin (MVAC) chemotherapy for the treatment of advanced bladder carcinoma. Int Urol Nephrol. 1993;25:351–357
  102. Long HJ, Langdon RM, Cha SS, et al.  Phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in advanced/recurrent endometrial carcinoma. Gynecol Oncol. 1995;58:240–243
  103. Haim N, Kedar A, Robinson E. Methotrexate-related deaths in patients previously treated with cis-diamminedichloride platinum. Cancer Chemother Pharmacol. 1984;13:223–225
  104. de Wit R, Stoter G, Kaye SB, et al.  Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol. 1997;15:1837–1843
  105. Ezzat AA, Raja MA, Berry J, Abd El-Warith A, Khan BA, Rhydderch DC. A prospective study of VEC-POB and POCE chemotherapy in aggressive non-Hodgkin's lymphoma. Am J Clin Oncol. 1997;20:179–183
  106. Bower M, Newlands ES, Holden L, Rustin GJ, Begent RH. Treatment of men with metastatic non-seminomatous germ cell tumours with cyclical POMB/ACE chemotherapy. Ann Oncol. 1997;8:477–483
  107. Fossa SD, Kaye SB, Mead GM, et al.  Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy: European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol. 1998;16:716–724
  108. Cvitkovic E. Bleomycin in nonseminomatous germ-cell tumors: cure rate versus morbidity. J Clin Oncol. 1998;16:799–800
  109. van Barneveld PWC, Sleijfer DT, van der Mark TW, et al.  Influence of platinum-induced renal toxicity on bleomycininduced pulmonary toxicity in patients with disseminated testicular carcinoma. Oncology. 1984;41:4–7
  110. Yee GC, Crom WR, Champion JE, et al.  Cisplatin-induced changes in bleomycin elimination. Cancer Treat Rep. 1983;67:587–589
  111. Bokemeyer C, Berger CC, Kuczyk MA, Schmoll HJ. Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol. 1996;14:2923–2932
  112. Blayney DW, Goldberg DA, Leong LA, Margolin KA, Burke JS, Doroshow JH. High-risk germ cell tumors in men. In: High response rate and severe toxicity with cisplatin, vinblastine, bleomycin, and etoposide. Cancer. 71:1993;p. 2351–2357
  113. Salem PA, Jabboury KW, Khalil ME. Severe nephrotoxicity: a probable complication of cis-dichlorodiammineplatinum (II) and cephalothin-gentamicin therapy. Oncology. 1982;39:31–32
  114. Walker EM, Fazekas-May MA, Bowen WR. Nephrotoxic and ototoxic agents. Clin Lab Med. 1990;10:323–354
  115. Gonzalez-Vitale JC, Hayes DM, Cvitkovic E, Sternberg SS. Acute renal failure after cis-dichlorodiammineplatinum(II) and centamicin-cephalothin therapies. Cancer Treat Rep. 1978;62:693–698
  116. Mollman JE. Cisplatin neurotoxicity. N Engl J Med. 1990;322:126–127
  117. Minami T, Ichii M, Okazaki Y. Detection of platinum in the brain of mice treated with cisplatin and subjected to shortterm hypoxia. J Pharm Pharmacol. 1996;48:505–509
  118. Zhou G, Lin S. The olfactory neurotoxicity of cisplatin and effects of two drugs. Chung Hua Erh Pi Yen Hou Ko Tsa Chih. 1995;30:233–235
  119. Mollman JE, Hogan WM, Glover DJ, et al.  Unusual presentation of cis-platinum neuropathy. Neurology. 1988;38:488–490
  120. Becher R, Schutt P, Osieka R, et al.  Peripheral neuropathy and ophthalmologic toxicity after treatment with cis-dichlorodiamminoplatinum II. J Cancer Res Clin Oncol. 1980;96:219–221
  121. Grunberg SM, Sonka S, Stevenson LL, et al.  Progressive paresthesias after cessation of therapy with very high-dose cisplatin. Cancer Chemother Pharmacol. 1989;25:62–64
  122. Fossa SD, Lehne G, Heimdal K, Theodorsen L. Clinical and biochemical long-term toxicity after postoperative cisplatinbased chemotherapy in patients with low-stage testicular cancer. Oncology. 1995;52:300–305
  123. Barajon I, Bersani M, Quartu M, et al.  Neuropeptides and morphological changes in cisplatin-induced dorsal root ganglion neuronopathy. Exp Neurol. 1996;138:93–104
  124. Cece R, Petruccioli MG, Cavaletti G, Barajon I, Tredici G. An ultrastructural study of neuronal changes in dorsal root ganglia (DRG) of rats after chronic cisplatin administrations. Histol Histopathol. 1995;10:837–845
  125. Russell JW, Windebank AJ, McNiven MA, Brat DJ, Brimijoin WS. Effect of cisplatin and ACTH4-9 on neural transport in cisplatin induced neurotoxicity. Brain Res. 1995;676:258–267
  126. Elderson A, Gerritsen van der Hoop R, Haanstra W, et al.  Vibration perception and thermoperception as quantitative measurements in the monitoring of cisplatin induced neurotoxicity. J Neurol Sci. 1989;93:167–174
  127. Roberts JA, Jenison EL, Kim K, Clarke-Pearson D, Langleben A. A randomized, multicenter, double-blind, placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer. Gynecol Oncol. 1997;67:172–177
  128. Fu KK, Kai EF, Leung CK. Cisplatin neuropathy: a prospective clinical and electrophysiological study in Chinese patients with ovarian carcinoma. J Clin Pharm Ther. 1995;20:167–172
  129. Higa GM, Wise TC, Crowell EB. Severe, disabling neurologic toxicity following cisplatin retreatment. Ann Pharmacother. 1995;29:134–137
  130. Vogelzang NJ, Bosl GJ, Johnson K, et al.  Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer. Ann Intern Med. 1981;95:288–292
  131. Doll DC, List AF, Greco FA, et al.  Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis. Ann Intern Med. 1986;105:48–51
  132. Helson L, Okonkwo E, Anton L, Cvitkovic E. cis-Platinum ototoxicity. Clin Toxicol. 1978;13:469–478
  133. Vermorken JB, Kapteijn TS, Hart AAM, et al.  Ototoxicity of cis-diamminedichloroplatinum (II): influence of dose, schedule and mode of administration. Eur J Cancer. 1983;19:53–58
  134. Fleming S, Peppard S, Ratanatharathom V, et al.  Ototoxicity from cis-platinum in patients with stages III and IV previously untreated squamous cell cancer of the head and neck. Am J Clin Oncol. 1985;8:302–306
  135. McHaney VA, Thibadoux G, Hayes FA, et al.  Hearing loss in children receiving cisplatin chemotherapy. J Pediatr. 1983;102:314–317
  136. Fausti SA, Larson VD, Noffsinger D, Wilson RH, Phillips DS, Fowler CG. High-frequency audiometric monitoring strategies for early detection of ototoxicity. Ear Hear. 1994;15:232–239
  137. Hallmark RJ, Snyder JM, Jusenius K, Tamimi HK. Factors influencing ototoxicity in ovarian cancer patients treated with Cis-platinum based chemotherapy. Eur I Gynaecol Onco1. 1992;13:35–44
  138. Waters GS, Ahmad M, Katsarkas A, Stanimir G, McKay J. Ototoxicity due to cis-diamminedichloroplatinum in the treatment of ovarian cancer: influence of dosage and schedule of administration. Ear Hear. 1991;12:91–102
  139. Melamed LB, Selim MA, Schuchman D. Cisplatin ototoxicity in gynecologic cancer patients. Cancer. 1985;55:41–43
  140. Skinner R, Pearson AD, Amineddine HA, Mathias DB, Craft AW. Ototoxicity of cisplatinum in children and adolescents. Br J Cancer. 1990;61:927–931
  141. Reddel RR, Kefford RF, Grant JM, et al.  Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration. Cancer Treat Rep. 1982;66:19–23
  142. Schaefer SD, Wright CG, Post JD, et al.  cis-Platinum vestibular toxicity. Cancer. 1981;47:847–859
  143. Simpson TH, Schwan SA, Rintelmann WF. Audiometric test criteria in the detection of cisplatin ototoxicity. J Am Acad Audiol. 1992;3:176–185
  144. Hansen SW, Helweg-Larsen S, Trojaborg W. Long-term neurotoxicity in patients treated with cisplatin, vinblastine, and bleomycin for metastatic germ cell cancer. J Clin Oncol. 1989;7:1457–1461
  145. Coupland SG, Ponton CW, Eggermont JJ, Bowen TJ, Grant RM. Assessment of cisplatin-induced ototoxicity using derived-band ABRs. Int J Pediatr Otorhinolaryngol. 1991;22:237–248
  146. Plinkert PK, Krober S. Early detection of cisplatin-induced ototoxicity using evoked otoacoustic emissions. Laryngorhinootologie. 1991;70:457–462
  147. Ozturan O, Jerger J, Lew H, Lynch GR. Monitoring of cisplatin ototoxicity by distortion-product otoacoustic emissions. Auris Nasus Larynx. 1996;23:147–151
  148. Zheng JL, Gao WQ. Differential damage to auditory neurons and hair cells by ototoxins and neuroprotection by specific neurotrophins in rat cochlear organotypic cultures. Eur I Neurosci. 1996;8:1897–1905
  149. Saito T, Manabe Y, Honda N, Yamada T, Yamamoto T, Saito H. Semiquantitative analysis by scanning electron microscopy of cochlear hair cell damage by ototoxic drugs. Scanning Microsc. 1995;9:271–280
  150. Saito T, Yamada T, Manabe Y, Yamamoto T, Saito H. Cisplatin metabolites and their toxicity on isolated cochlear outer hair cells in vitro. Acta Otolaryngol (Stockh). 1996;116:561–565
  151. Ravi R, Somani SM, Rybak LP. Mechanism of cisplatin ototoxicity: antioxidant system. Pharmacol Toxicol. 1995;76:386–394
  152. Belli L, Lechevalier T, Gottfried M, et al.  Phase I/II study of paclitaxel plus cisplatin as first-line chemotherapy for advanced non-small cell lung cancer: preliminary results. Semin Oncol. 1995;22(6 Suppl. 15):29–33
  153. Connelly E, Markman M, Kennedy A, et al.  Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity. Gynecol Oncol. 1996;62:166–168
  154. Cavaletti G, Bogliun G, Crespi V, et al.  Neurotoxicity and ototoxicity of cisplatin plus paclitaxel in comparison to cisplatin plus cyclophosphamide in patients with epithelial ovarian cancer. J Clin Oncol. 1997;15:199–206
  155. Kelsen D, Ginsberg R, Bains M, et al.  A phase II trial of paclitaxel and cisplatin in patients with locally advanced metastatic esophageal cancer: a preliminary report. Semin Oncol. 1997;24(6 Suppl. 19):S19–S77
  156. Roytta M, Horwitz SB, Raine CS. Taxol-induced neuropathy: short-term effects of local injection. J Neurocytol. 1984;13:685–701
  157. Gordon AN, Stringer CA, Matthews CM, Willis DL, Nemunaitis J. Phase I dose escalation of paclitaxel in patients with advanced ovarian cancer receiving cisplatin: rapid development of neurotoxicity is dose-limiting. J Clin Oncol. 1997;15:1965–1973
  158. Berger T, Malayeri R, Doppelbauer A, et al.  Neurological monitoring of neurotoxicity induced by paclitaxel/cisplatin chemotherapy. Eur J Cancer. 1997;33:1393–1399
  159. Hilkens PH, Pronk LC, Verweij J, Vecht CJ, van Putten WL, van den Bent MJ. Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin. Br J Cancer. 1997;75:417–422
  160. Pace A, Bove L, Aloe A, et al.  Paclitaxel neurotoxicity: clinical and neurophysiological study of 23 patients. Ital J Neurol Sci. 1997;18:73–79
  161. Cavaletti G, Bogliun G, Marzorati L, et al.  Peripheral neurotoxicity of taxol in patients previously treated with cisplatin. Cancer. 1995;75:1141–1150
  162. Cvitkovic E, Spaulding J, Bethune V, et al.  Improvement of cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model. Cancer. 1977;39:1357–1361
  163. Frick GA, Ballentine R, Driever CW, et al.  Renal excretion kinetics of high-dose cis-dichlorodiammineplatinum (II) administered with hydration and mannitol diuresis. Cancer Treat Rep. 1979;63:13–16
  164. Cornelison TL, Reed E. Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol. 1993;50:147–158
  165. Litterst CL. Allterations in the toxicity of cis-dichlorodiammineplatinum-Ii; in tissue localization of platinum as a function of Nacl concentration in the vehicle of administration. Toxicol Appl Pharmacol. 1981;61:99–108
  166. Ozols RF, Corden BJ, Jacob J, et al.  High-dose cisplatin in hypertonic saline. Ann Intern Med. 1984;100:19–24
  167. Dimery IW, Legha SS. Sequential methotrexate, 5-fluorouracil, and cisplatin in the treatment of recurrent squamous-cell carcinoma of the head and neck: failure of hypertonic saline to reduce the nephrotoxicity of cisplatin. J Clin Oncol. 1986;4:1670–1676
  168. Legha SS, Dimery IW. High-dose cisplatin administration without hypertonic saline: observation of disabling neurotoxicity. J Clin Oncol. 1985;3:1373–1378
  169. Soulié P, Ruffié L, Trandafir L, et al.  Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma: report of a phase I–II study of weekly cisplatin/interferon alfa-2a. J Clin Oncol. 1996;14:878–885
  170. Borch RF, Markman M. Biochemical modulation of cisplatin toxicity. Pharmacol Ther. 1989;41:371–380
  171. Grdina DJ, Guilford WH, Sigdestad CP, et al.  Effects of radioprotectors on DNA damage and repair, proteins, and cell-cycle progression. Pharmacol Ther. 1988;39:133–137
  172. Yuhas JM. Biological factors affecting the radioprotective efficiency of S-2-[3-aminopropylamino] ethylphosphorothioic acid (WR-2721). LD50(30) doses. Radiat Res. 1970;44:621–628
  173. Treskes M, Nijtmans LGJ, Fichtinger-Schepman AMJ, et al.  Effects of the modulating agent WR2721 and its main metabolites on the formation and stability of cisplatin-DNA adducts in vitro in comparison to the effects of thiosulphate and diethyldithiocarbamate. Biochem Pharmacol. 1992;43:1013–1019
  174. Calabro-Jones PM, Aguilera JA, Ward JF, et al.  Uptake of WR-2721 derivatives by cells in culture: identification of the transported form of the drug. Cancer Res. 1988;48:3634–3640
  175. Grdina DJ, Shigematsu N, Dale P, et al.  Thiol and disulfide metabolites of the radiation protector and potential chemopreventive agent WR-2721 are linked to both its anti-cytotoxic and anti-mutagenic mechanisms of action. Carcinogenesis. 1995;16:767–774
  176. Liu SC, Murley JS, Woloschak G, Grdina DJ. Repression of c-myc gene expression by the thiol and disulfide forms of the cytoprotector amifostine. Carcinogenesis. 1997;18:2457–2459
  177. Murley JS, Constantinou A, Kamath NS, Grdina DJ. WR-1065, an active metabolite of the cytoprotector amifostine, affects phosphorylation of topoisomerase II alpha leading to changes in enzyme activity and cell cycle progression in CHO AA8 cells. Cell Prolif. 1997;30:283–294
  178. Yuhas JM, Culo F. Selective inhibition of the nephrotoxicity of cis-dichlorodiammineplatinum(II) by WR-2721 without altering its antitumor properties. Cancer Treat Rep. 1980;64:57–64
  179. Yuhas JM, Spellman JM, Jordan SW, et al.  Treatment of tumours with combination of WR-2721 and cis-dichlorodiammineplatinum (II) or cyclophosphamide. Br J Cancer. 1980;42:574–585
  180. Fichtner I, Lemm M, Becker M, Berthold F. Effects of amifostine (WR-2721, ethyol) on tumor growth and pharmacology of cytotoxic drugs in human xenotransplanted neuroblastomas. Anticancer Drugs. 1997;8:174–181
  181. Treskes M, Boven E, Holwerda U, et al.  Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR2721 in the mouse. Cancer Res. 1992;52:2257–2260
  182. Mollman JE. Protection against cis-platin neurotoxicity in cultured dorsal root ganglion cells by WR-2721. In: Proceedings of the 7th International Conference of Chemical Modifiers of Cancer Treatment. 1991;p. 328
  183. Müller LJ, Moorer-Van Delft CM, Treskes M, et al.  WR-2721 protects neurons of the snail Lymnaea stagnalis from cisplatin-induced toxicity. In: Proc AACR. 33:1992;p. 557 Müller LJ, Moorer-Van Delft CM, Treskes M, et al.  WR-2721 protects neurons of the snail Lymnaea stagnalis from cisplatin-induced toxicity. In: Proc AACR. 33:1992;p. A3330
  184. Glover D, Glick JH, Weiler C, et al.  WR-2721 and high-dose cisplatin: An active combination in the treatment of metastatic melanoma. J Clin Oncol. 1987;5:574–578
  185. Avril MF, Ortoli JC, Fortier-Beaulieu M, et al.  High dose cisplatin (C) and WR 2721 in metastatic melanoma. In: Proc ASCO. 11:1992;p. 344 Avril MF, Ortoli JC, Fortier-Beaulieu M, et al.  High dose cisplatin (C) and WR 2721 in metastatic melanoma. In: Proc ASCO. 11:1992;p. A1181
  186. Rubin JS, Wadler S, Beitler JJ, et al.  Audiological findings in a phase I protocol investigating the effect of WR 2721, highdose cisplatin and radiation therapy in patients with locally advanced cervical carcinoma. J Laryngol Otol. 1995;109:744–747
  187. Bokemeyer C, Hartmann JT, Fels L, et al.  Amifostine protects against early cisplatin-induced renal damage and enhances CD34 cell numbers for PBSC collection. In: Proc ASCO. 16:1997;p. A166; (abstract)
  188. Tannehill SP, Mehta MP, Larson M, et al.  Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer: results of a phase II trial. J Clin Oncol. 1997;15:2850–2857
  189. Ramnath N, Lorusso P, Simon M, Martino S. Phase II evaluation of cisplatin and WR2721 for refractory metastatic breast cancer. Am J Clin Oncol. 1997;20:368–372
  190. De la Garza SJ. Cisplatin (CDDP), radiotherapy (RT) and amifostine (WR-2721) in advanced and previously untreated cervical cancer: phase II study. In: ]Proc ASCO. 16:1997;p. A1317; (abstract)
  191. Giglio R, Mickiewicz E, Pradier E, et al.  Alternating chemotherapy (ct) + radiotherapy (rt) with amifostine (a) protection for head; neck cancer (hn). In: Early stop of a randomized trial. Proc Asco. 16:1997;p. A1369; abstract
  192. Kemp G, Rose P, Lurain J, et al.  Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatininduced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol. 1996;14:2101–2112
  193. Planting AST, Vermorken JB, Catimel G, et al.  Randomized phase II study of weekly cisplatin with or without amifostine in patients with advanced head and neck cancer. Ann Oncol. 1996;7(Suppl. 5):79 Planting AST, Vermorken JB, Catimel G, et al.  Randomized phase II study of weekly cisplatin with or without amifostine in patients with advanced head and neck cancer. Ann Oncol. 1996;7(Suppl. 5):A374P
  194. Borch RF, Pleasants ME. Inhibition of cis-platinum nephrotoxicity by diethyldithiocarbamate rescue in a rat model. In: Proc Natl Acad Sci USA. 76:1979;p. 6611–6614
  195. Borch RF, Katz JC, Lieder PH, et al.  Effect of diethlydithiocarbamate rescue on tumor response to cis-platinum in a rat model. In: Proc Natl Acad Sci USA. 77:1980;p. 5441–5444
  196. Somani SM, Ravi R, Rybak LP. Diethyldithiocarbamate protection against cisplatin nephrotoxicity: antioxidant system. Drug Chem Toxicol. 1995;18:151–170
  197. Rybak LP, Ravi R, Somani SM. Mechanism of protection by diethyldithiocarbamate against cisplatin ototoxicity: antioxidant system. Fundam Appl Toxicol. 1995;26:293–300
  198. Church MW, Kaltenbach JA, Blakley BW, Burgio DL. The comparative effects of sodium thiosulfate, diethyldithiocarbamate, fosfomycin and WR-2721 on ameliorating cisplatin-induced ototoxicity. Hear Res. 1995;86:195–203
  199. Berry JM, Jacobs C, Sikic B, et al.  Modification of cisplatin toxicity with diethyldithiocarbamate. J Clin Oncol. 1990;8:1585–1590
  200. Qazi R, Chang AYC, Borch RF, et al.  Phase I clinical and pharmacokinetic study of diethyldithiocarbamate as a chemoprotector from toxic effects of cisplatin. J Natl Cancer Inst. 1988;80:1486–1488
  201. Cvitkovic E, Hayes DM, Golbey RB, Krakoff IH. Cisplatin nephrotoxicity: diethyldithiocarbamate, WR2721, or just water?. J Clin Oncol. 1991;9:707–709
  202. Gandara DR, Wiebe VJ, Perez EA, et al.  Cisplatin rescue therapy: experience with sodium thiosulfate, WR2721, and diethyldithiocarbamate. Crit Rev Oncol Hematol. 1990;10:353–365
  203. Paredes J, Hong WK, Felder TB, et al.  Prospective randomized trial of high-dose cisplatin; fluorouracil infusion with or without sodium diethyldithiocarbamate in recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 1988;6:955–962
  204. Gandara DR, Nahhas WA, Adelson MD, et al.  Randomized placebo-controlled multicenter evaluation of diethyl-dithiocarbamate for chemoprotection against cisplatin-induced toxicities. J Clin Oncol. 1995;13:490–496
  205. Welters MJ, Fichtinger-Schepman AM, Baan RA, Flens MJ, Scheper RJ, Braakhuis BJ. Role of glutathione, glutathione S-transferases and multidrug resistance-related proteins in cisplatin sensitivity of head and neck cancer cell lines. Br J Cancer. 1998;77:556–561
  206. Lautermann J, Crann SA, McLaren J, Schacht J. Glutathionedependent antioxidant systems in the mammalian inner ear: effects of aging, ototoxic drugs and noise. Hear Res. 1997;114:75–82
  207. Li XM, Metzger G, Filipski E, et al.  Pharmacologic modulation of reduced glutathione circadian rhythms with buthionine sulfoximine: relationship with cisplatin toxicity in mice. Toxicol Appl Pharmacol. 1997;143:281–290
  208. Hahn R, Wendel A, Floh L. The fate of extracellular glutathione in the rat. Biochim Biophys Acta. 1978;539:324–337
  209. Romero FJ, Segura-Aguilar J, Monsalve E, et al.  Antioxidant and glutathione-related enzymatic activities in rat sciatic nerve. Neurotoxicol Teratol. 1990;12:603–605
  210. Anderson ME, Naganuma A, Meister A. Protection against cisplatin toxicity by administration of glutathione ester. FASEB J. 1990;4:3251–3255
  211. Babu E, Gopalakrishnan VK, Sriganth INP, et al.  Cisplatin induced nephrotoxicity and the modulating effect of glutathione ester. Mol Cell Biochem. 1995;144:7–11
  212. Hamers FPT, Brakkee JH, Cavalletti E, et al.  Reduced glutathione protects against cisplatin-induced neurotoxicity in rats. Cancer Res. 1993;53:544–549
  213. Plaxe S, Freddo J, Kim S, et al.  Phase I trial of cisplatin in combination with glutathione. Gynecol Oncol. 1993;55:82–86
  214. Cozzaglio L, Doci R, Colella G, et al.  A feasibility study of high-dose cisplatin and 5-fluorouracil with glutathione protection in the treatment of advanced colorectal cancer. Tumori. 1990;76:590–594
  215. Gebbia V, Valenza R, Testa A, et al.  Weekly 5-fluorouracil and folinic acid plus escalating doses of cisplatin with glutathione protection in patients with advanced head and neck cancer. Med Oncol Tumor Pharmacother. 1992;9:165–168
  216. Fontanelli R, Spatti G, Raspagliesi F, et al.  A preoperative single course of high-dose cisplatin and bleomycin with glutathione protection in bulky stage IB/II carcinoma of the cervix. Ann Oncol. 1992;3:117–121
  217. Di Re F, Bohm S, Oriana S, et al.  High-dose cisplatin and cyclophosphamide with glutathione in the treatment of advanced ovarian cancer. Ann Oncol. 1993;4:55–61
  218. Bogliun G, Marzorati L, Cavaletti G, et al.  Evaluation by somatosensory evoked potentials of the neurotoxicity of cisplatin alone or in combination with glutathione. Ital J Neurol Sci. 1992;13:643–647
  219. Cascinu S, Cordella L, Del Ferro E, et al.  Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebocontrolled trial. J Clin Oncol. 1995;13:26–32
  220. Cascinu S, Labianca R, Alessandroni P, et al.  Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epidoxorubicin, 6S-leucovorin, glutathione, and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer. J Clin Oncol. 1997;15:3313–3319
  221. Shea M, Koziol JA, Howell SB. Kinetics of sodium thiosulfate, a cisplatin neutralizer. Clin Pharmacol Ther. 1984;35:419–425
  222. Iwamoto Y, Kawano T, Ishizawa M, et al.  Inactivation of cisdiamminedichloroplatinum (II) in blood and protection of its toxicity by sodium thiosulfate in rabbits. Cancer Chemother Pharmacol. 1985;15:228–232
  223. Iwamoto Y, Kawano T, Uozumi J, et al.  ‘Two-route chemotherapy’ using high-dose ip cisplatin and iv sodium thiosulphate, its antidote, for peritoneally disseminated cancer in mice. Cancer Treat Rep. 1984;68:1367–1373
  224. Ueda H, Sugiyama K, Tashiro S, Yokota M. Mechanism of the protective effect of sodium malate on cisplatin-induced toxicity in mice. Biol Pharm Bull. 1998;21:121–128
  225. lannotti N, Markman M, D'Acquisto R, et al.  Phase I trial of escalating doses of intravenous (IV) cisplatin (C) and IV sodium thiosulfate (STS) renal protection. In: Proc ASCO. 7:1988;p. 55 lannotti N, Markman M, D'Acquisto R, et al.  Phase I trial of escalating doses of intravenous (IV) cisplatin (C) and IV sodium thiosulfate (STS) renal protection. In: Proc ASCO. 7:1988;p. A207
  226. Pfeifle CE, Howell SB, Felthouse RD, et al.  High-dose cisplatin with sodium thiosulfate protection. J Clin Oncol. 1985;3:237–244
  227. Zylberberg B, Dormont D, Antoine JM, et al.  First line immunochemotherapy with cisplatin-based protocol by intraperitoneal and intravenous routes in ovarian cancer: technique and results of 82 cases. Eur J Obstet Gynecol Reprod Biol. 1996;66:57–64
  228. Markman M, D'Acquisto R, lannotti N, et al.  Phase-1 trial of high-dose intravenous cisplatin with simultaneous intravenous sodium thiosulfate. J Cancer Res Clin Oncol. 1991;117:151–155
  229. Bonetti A, Howell SB, McClay E, et al.  High-dose biweekly intraperitoneal cisplatin: an effective way to increase cisplatin dose intensity. Gynecol Oncol. 1993;49:318–324
  230. Markman M, Cleary S, Howell SB. Nephrotoxicity of highdose intracavitary cisplatin with intravenous thiosulfate protection. Eur J Cancer. 1985;21:1015–1018
  231. Howell SB, Pfeifle CL, Wung WE, et al.  Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med. 1982;97:845–851
  232. Guastalla JP, Vermorken JB, Wils JA, et al.  Phase II trial for intraperitoneal cisplatin plus intravenous sodium thiosulphate in advanced ovarian carcinoma patients with minimal residual disease after cisplatin-basedfchemotherapy: a phase II study of the EORTC Gynaecological Cancer Cooperative Group. Eur J Cancer. 1994;30A:45–49
  233. Malmstrom H, Rasmussen S, Simonsen E. Intraperitoneal high-dose cisplatin and etoposide with systemic thiosulfate protection in second-line treatment oz advanced ovarian cancer. Gynecol Oncol. 1993;49:166–171
  234. de Jong RS, Willemse PH, Boonstra H, et al.  Phase II study of intraperitoneal cisplatin plus systemic etoposide as secondline treatment in patients with small volume residual ovarian cancer. Eur J Cancer. 1995;31A:709–713
  235. van Rijswijk RE, Hoekman K, Burger CW, Verheijen RH, Vermorken JB. Experience with intraperitoneal cisplatin and etoposide and i.v. sodium thiosulphate protection in ovarian cancer patients with either pathologically complete response or minimal residual disease. Ann Oncol. 1997;8:1235–1241
  236. Menczer J, Ben-Baruch G, Rizel S, Brenner H. Acute renal failure associated with intraperitoneal cisplatin chemotherapy with systemic thiosulfate protection in ovarian cancer patients. Eur J Gynaecol Oncol. 1991;12:403–406
  237. Gerritsen van der Hoop R, Vecht CJ, van der Burg MEL, et al.  Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer. N Engl J Med. 1990;322:89–94
  238. Tonnaer JADM, Schuijers GJPT, Van Diepen HA, et al.  Enhancement of regeneration by ORG 2766 after nerve crush depends on the type of neural injury. Eur J Pharmacol. 1992;214:33–37
  239. de Groot JC, Harriers FP, Gispen WH, et al.  Co-administration of the neurotrophic ACTH(4-9) analogue, ORG 2766, may reduce the cochleotoxic effects of cisplatin. Hear Res. 1997;106:9–19
  240. Neijt J, van der Burg M, Vecht C, et al.  A double-blind randomised study with ORG-2766 an ACTH(4-9) analog, to prevent cisplatin neuropathy. In: Proc ASCO. 13:1994;p. 261 Neijt J, van der Burg M, Vecht C, et al.  A double-blind randomised study with ORG-2766 an ACTH(4-9) analog, to prevent cisplatin neuropathy. In: Proc ASCO. 13:1994;p. A837
  241. Ohtani I, Ohtsuski K, Aikawa T, et al.  Protective effect of fosfomycin against aminoglycoside ototoxicity. ORL J Otorhinolaryngol Relat Spec. 1985;47:42–48
  242. Schweitzer VG, Dolan DF, Abrams GE, et al.  Amelioration of cisplatin-induced ototoxicity by fosfomycin. Laryngoscope. 1986;96:948–958
  243. Ohtani I, Ohtsuki K, Aikawa T. Reduction of cisplatin toxicity by fosfomycin in animal models. Jpn I Cancer Chemother. 1984;11:2400–2407
  244. Kurebe M, Niizato T, Sanda M, et al.  Preventive effect of fosfomycin on the renal toxicity of cisplatin. Jpn J Antibiot. 1985;38:62–68
  245. Umeki S, Watanabe M, Yagi S, et al.  Supplemental fosfomycin and/or steroids that reduce cisplatin-induced nephrotoxicity. Am J Med Sci. 1988;295:6–10
  246. Ciges M, Fernandez-Cervilla F, Crespo PV, Campos A. Pantothenic acid and coenzyme A in experimental cisplatin-induced ototoxia. Acta Otolaryngol (Stockh). 1996;116:263–268
  247. Boogaarct PJ, Lempers EL, Mulders GJ, Meerman JH. 4-Methylthiobenzoic acid reduces cisplatin nephrotoxicity in rats without compromising anti-tumour activity. Biochem Pharmacol. 1991;41:1997–2003
  248. Rybak LP, Husain K, Evenson L, Morris C, Whitworth C, Somani SM. Protection by 4-methylthiobenzoic acid against cisplatin-induced ototoxicity: antioxidant system. Pharmacol Toxicol. 1997;81:173–179
  249. Malgrange B, Delree P, Rigo JM, Baron H, Moonen G. Image analysis of neuritic regeneration by adult rat dorsal root ganglion neurons in culture: quantification of the neurotoxicity of anticancer agents and of its prevention by nerve growth factor or basic fibroblast growth factor but not brainderived neurotrophic factor or neurotrophin-3. J Neurosci Methods. 1994;53:111–122
  250. Zheng JL, Stewart RR, Gao WQ. Neurotrophin-4/5, brainderived neurotrophic factor, and neurotrophin-3 promote survival of cultured vestibular ganglion neurons and protect them against neurotoxicity of ototoxins. J Neurobiol. 1995;28:330–340
  251. Zheng JL, Stewart RR, Gao WQ. Neurotrophin-4/5 enhances survival of cultured spiral ganglion neurons and protects them from cisplatin neurotoxicity. J Neurosci. 1995;15:5079–5087
  252. Gabaizadeh R, Staecker H, Liu W, et al.  Protection of both auditory hair cells and auditory neurons from cisplatin induced damage. Acta Otolaryngol. 1997;117:232–238
  253. Campbell KC, Rybak LP, Meech RP, Hughes L. D-methionine provides excellent protection from cisplatin ototoxicity in the rat. Hear Res. 1996;102:90–98
  254. Gao WQ, Dybdal N, Shinsky N, et al.  Neurotrophin-3 reverses experimental cisplatin-induced peripheral sensory neuropathy. Ann Neurol. 1995;38:30–37
  255. Schweitzer VG. Cisplatin-induced ototoxicity: the effect of pigmentation and inhibitory agents. Laryngoscope. 1993;103:1–52
  256. Holding JD, Stell PM, Lindup WE. Failure of a 21-aminosteroid antioxidant to ameliorate cisplatin-induced nephrotoxicity. Hum Exp Toxicol. 1991;10:323–326
  257. Tokunaga J, Nakamura C, Kitagawa A, Kobayashi M, Arimori K, Nakano M. Protective effects of betamipron on renal toxicity during repeated cisplatin administration in rats and protective mechanism. Ren Fail. 1998;20:27–38
  258. Jacobs C, Kaubisch S, Halsey J, et al.  The use of probenecid as a chemoprotector against cisplatin nephrotoxicity. Cancer. 1991;67:1518–1524
  259. Bokemeyer C, Fels LM, Dunn T, et al.  Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumour activity. Br J Cancer. 1996;74:2036–2041
  260. Satoh M, Aoki Y, Tohyama C. Protective role of metallothionein in renal toxicity of cisplatinum. Cancer Chemother Pharmacol. 1997;40:358–362

PII: S0305-7372(98)90061-5

Cancer Treatment Reviews
Volume 24, Issue 4 , Pages 265-281 , August 1998

Article Tools